As countries begin using a new drug to treat multidrug-resistant tuberculosis (MDR-TB), authorities urge caution to prevent drug resistance from emerging and to protect patients from potential adverse effects.
Bedaquiline is the first TB drug with a novel mechanism to be approved in 40 years. However, the World Health Organization (WHO) cautioned that the drug has not yet completed the final phase of clinical testing. The US Food and Drug Administration fast-tracked bedaquiline’s approval through its orphan drug program. In an unprecedented step, the WHO issued an interim guidance on using the drug.
From JAMA’s Daily News Site. JAMA. 2013;310(9):893. doi:10.1001/jama.2013.276468
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: